Last reviewed · How we verify

valsartan/amlodpine — Competitive Intelligence Brief

valsartan/amlodpine (valsartan/amlodpine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Calcium channel blocker combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

valsartan/amlodpine (valsartan/amlodpine) — University of Pavia. Valsartan/amlodipine is a combination of an angiotensin II receptor blocker and a calcium channel blocker that reduces blood pressure through dual vasodilation and reduced vasoconstriction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
valsartan/amlodpine TARGET valsartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
valsartan/amlodipine valsartan/amlodipine Novartis marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
Irbesartan/Amlodipine high Irbesartan/Amlodipine high Handok Inc. phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
Irbesartan/Amlodipine low Irbesartan/Amlodipine low Handok Inc. phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
Irbesartan/Amlodipine Irbesartan/Amlodipine Handok Inc. phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
Fimasartan/Amlodipine, Rosuvastatin Fimasartan/Amlodipine, Rosuvastatin Boryung Pharmaceutical Co., Ltd phase 3 Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin) AT1 receptor / L-type calcium channel / HMG-CoA reductase
Fimasartan/Amlodipine combination Fimasartan/Amlodipine combination Boryung Pharmaceutical Co., Ltd phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Calcium channel blocker combination class)

  1. Handok Inc. · 3 drugs in this class
  2. Institut für Pharmakologie und Präventive Medizin · 2 drugs in this class
  3. Chong Kun Dang Pharmaceutical · 1 drug in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. HK inno.N Corporation · 1 drug in this class
  6. Novartis · 1 drug in this class
  7. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
  8. University of Pavia · 1 drug in this class
  9. COLM Study Research Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). valsartan/amlodpine — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-amlodpine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: